{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:13:57Z","timestamp":1792030437079,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.cca.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T11:07:12Z","timestamp":1413630432000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Galectin-3 and heart failure: Prognosis, prediction & clinical utility"],"prefix":"10.1016","volume":"443","author":[{"given":"Mando D.","family":"Filipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rogier van der Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0005","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/heart.83.5.596","article-title":"Epidemiology, aetiology, and prognosis of heart failure","volume":"83","author":"McMurray","year":"2000","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/HCO.0b013e32834fdc98","article-title":"Recent advances in the management of chronic heart failure","volume":"27","author":"Haddad","year":"2012","journal-title":"Curr Opin Cardiol"},{"issue":"24","key":"10.1016\/j.cca.2014.10.009_bb0015","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.cca.2014.10.009_bb0020","first-page":"269","article-title":"Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives","volume":"106","author":"Neumann","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"10.1016\/j.cca.2014.10.009_bb0025","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/CIRCULATIONAHA.109.192666","article-title":"Executive summary: heart disease and stroke statistics\u20142010 update: a report from the American Heart Association","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cca.2014.10.009_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11897-012-0114-8","article-title":"Aging of the United States population: impact on heart failure","volume":"9","author":"Vigen","year":"2012","journal-title":"Curr Heart Fail Rep"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0035","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","article-title":"Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH","volume":"6","author":"van der Velde","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.cca.2014.10.009_bb0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2009.08.078","article-title":"N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study","volume":"55","author":"Berger","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.cca.2014.10.009_bb0050","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/ajkd.2003.50118","article-title":"B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study","volume":"41","author":"McCullough","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cca.2014.10.009_bb0065","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2003.10.066","article-title":"Obesity and suppressed B-type natriuretic peptide levels in heart failure","volume":"43","author":"Mehra","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cca.2014.10.009_bb0070","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: a novel mediator of heart failure development and progression","volume":"11","author":"de Boer","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.cca.2014.10.009_bb0075","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s003359900548","article-title":"Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22","volume":"8","author":"Raimond","year":"1997","journal-title":"Mamm Genome"},{"issue":"4","key":"10.1016\/j.cca.2014.10.009_bb0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.cca.2014.10.009_bb0085","first-page":"1016","article-title":"Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages","volume":"147","author":"Liu","year":"1995","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1172\/JCI31044","article-title":"ECM remodeling in hypertensive heart disease","volume":"117","author":"Berk","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2013.08.081","article-title":"Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction","volume":"169","author":"Carrasco-Sanchez","year":"2013","journal-title":"Int J Cardiol"},{"issue":"19","key":"10.1016\/j.cca.2014.10.009_bb0105","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0110","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0120","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.ijcard.2013.12.129","article-title":"Galectin-3 expression in cardiac remodeling after myocardial infarction","volume":"172","author":"Sanchez-Mas","year":"2014","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"10.1016\/j.cca.2014.10.009_bb0130","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"7\u20138","key":"10.1016\/j.cca.2014.10.009_bb0145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinbiochem.2010.02.001","article-title":"Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure","volume":"43","author":"Christenson","year":"2010","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/14737159.2014.892421","article-title":"The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure","volume":"14","author":"Meijers","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.cca.2014.10.009_bb0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cca.2013.12.017","article-title":"Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction","volume":"429","author":"Gruson","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.cca.2014.10.009_bb0160","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"12 Suppl 1","key":"10.1016\/j.cca.2014.10.009_bb0165","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.09.011","article-title":"Congestion in acute heart failure syndromes: an essential target of evaluation and treatment","volume":"119","author":"Gheorghiade","year":"2006","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jacc.2012.08.1022","article-title":"Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization","volume":"61","author":"Collins","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/HPC.0000000000000012","article-title":"Emergency department use of galectin-3","volume":"13","author":"Peacock","year":"2014","journal-title":"Crit Pathw Cardiol"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0180","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"issue":"10","key":"10.1016\/j.cca.2014.10.009_bb0190","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/eurjhf\/hft077","article-title":"Galectin-3 in heart failure with preserved ejection fraction","volume":"15","author":"de Boer","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0195","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","article-title":"Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials","volume":"167","author":"Meijers","year":"2014","journal-title":"Am Heart J"},{"issue":"17","key":"10.1016\/j.cca.2014.10.009_bb0200","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2012.06.040","article-title":"Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score","volume":"60","author":"Eurlings","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.cca.2014.10.009_bb0205","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3109\/1354750X.2012.719037","article-title":"Galectin 3 complements BNP in risk stratification in acute heart failure","volume":"17","author":"Fermann","year":"2012","journal-title":"Biomarkers"},{"key":"10.1016\/j.cca.2014.10.009_bb0210","doi-asserted-by":"crossref","first-page":"983098","DOI":"10.1155\/2014\/983098","article-title":"Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure","volume":"2014","author":"De Berardinis","year":"2014","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0215","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ahj.2013.02.029","article-title":"Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results","volume":"165","author":"Wu","year":"2013","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/eurjhf\/hfs205","article-title":"Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT","volume":"15","author":"Anand","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.cca.2014.10.009_bb0225","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurjhf\/hft075","article-title":"Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study","volume":"15","author":"Motiwala","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"1\u20132","key":"10.1016\/j.cca.2014.10.009_bb0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cca.2009.09.001","article-title":"The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients","volume":"409","author":"Lin","year":"2009","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0235","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00392-012-0500-y","article-title":"Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure","volume":"102","author":"Lok","year":"2013","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0245","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jchf.2013.12.004","article-title":"Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure","volume":"2","author":"Ahmad","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0255","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ahj.2012.08.021","article-title":"The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"164","author":"Gullestad","year":"2012","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0260","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.cca.2014.10.009_bb0265","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.cca.2014.10.009_bb0270","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/eurheartj\/ehl193","article-title":"EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population","volume":"27","author":"Nieminen","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1373\/clinchem.2011.174359","article-title":"Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22","volume":"58","author":"Grandin","year":"2012","journal-title":"Clin Chem"},{"issue":"14","key":"10.1016\/j.cca.2014.10.009_bb0280","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0285","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.21","article-title":"Plasma galectin 3 and heart failure risk in the Physicians' Health Study","volume":"16","author":"Djousse","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0290","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/CIRCHEARTFAILURE.114.001185","article-title":"Clinical risk stratification optimizes value of biomarkers to predict new onset heart failure in a community-based cohort","volume":"7","author":"Brouwers","year":"2014","journal-title":"Circ Heart Fail Sep"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0295","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ahj.2014.02.009","article-title":"Galectin 3 and incident atrial fibrillation in the community","volume":"167","author":"Ho","year":"2014","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.cca.2014.10.009_bb0300","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0305","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5603\/CJ.2013.0157","article-title":"The association between galectin-3 and clinical parameters in patients with fi rst acute myocardial infarction treated with primary percutaneous coronary angioplasty","volume":"20","author":"Szadkowska","year":"2013","journal-title":"Cardiol J"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0310","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/CIRCHEARTFAILURE.112.000146","article-title":"Galectin-3 and cardiac function in survivors of acute myocardial infarction","volume":"6","author":"Weir","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.cca.2014.10.009_bb0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CRD.0b013e3182769073","article-title":"Using biomarkers to \u201cguide\u201d heart failure management: current perspectives and future directions","volume":"21","author":"Motiwala","year":"2013","journal-title":"Cardiol Rev"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0320","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/HCO.0b013e3283587c4d","article-title":"Use of biomarkers to guide outpatient therapy of heart failure","volume":"27","author":"DeBeradinis","year":"2012","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0325","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cardfail.2013.11.011","article-title":"Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION","volume":"20","author":"Fiuzat","year":"2014","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.cca.2014.10.009_bb0330","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jce.12364","article-title":"Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators","volume":"25","author":"Francia","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"10","key":"10.1016\/j.cca.2014.10.009_bb0335","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1515\/cclm-2014-0278","article-title":"Practical experience using galectin-3 in heart failure","volume":"52","author":"McCullough","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"16","key":"10.1016\/j.cca.2014.10.009_bb0340","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cca.2014.10.009_bb0345","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O'Seaghdha","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.cca.2014.10.009_bb0350","doi-asserted-by":"crossref","first-page":"e18683","DOI":"10.1371\/journal.pone.0018683","article-title":"Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury","volume":"6","author":"Kolatsi-Joannou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2014.10.009_bb0355","doi-asserted-by":"crossref","first-page":"e000962","DOI":"10.1161\/JAHA.114.000962","article-title":"Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis","volume":"3","author":"Meijers","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"2\u20133","key":"10.1016\/j.cca.2014.10.009_bb0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0304-4165(02)00315-X","article-title":"Galectins and cancer","volume":"1572","author":"Danguy","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"7\u20139","key":"10.1016\/j.cca.2014.10.009_bb0365","first-page":"537","article-title":"Expression of galectins in cancer: a critical review","volume":"19","author":"van den Brule","year":"2004","journal-title":"Glycoconj J"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0370","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrc1527","article-title":"Galectins as modulators of tumour progression","volume":"5","author":"Liu","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.cca.2014.10.009_bb0375","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1515\/cclm-2014-0239","article-title":"The role of glycemia in acute heart failure patients","volume":"52","author":"Seferovic","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"10.1016\/j.cca.2014.10.009_bb0380","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1515\/cclm-2014-0265","article-title":"Structural myocardial alterations in diabetes and hypertension: the role of galectin-3","volume":"52","author":"Seferovic","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.cca.2014.10.009_bb0385","first-page":"79","article-title":"Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure","volume":"11","author":"Yin","year":"2014","journal-title":"J Geriatr Cardiol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114004409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114004409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T12:20:19Z","timestamp":1538137219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898114004409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":77,"alternative-id":["S0009898114004409"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2014.10.009","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 and heart failure: Prognosis, prediction & clinical utility","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}